Full history for every metric is available with a Kvantra account
Hainan Poly Pharm. Co., Ltd (300630.SZ)
Key financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 624 | 950 | 1,189 | 1,509 | 1,619 | 1,304 | 577 |
| Operating profit | CNY m | 48 | 345 | |||||
| Net profit | CNY m | 181 | 301 | 407 | 417 | 295 | 86 | -106 |
| EPS reported | CNY | 0.19 | -0.98 | |||||
| Operating cashflow per share | CNY | 0.25 | 0.25 | |||||
| Capex per share | CNY | 1.21 | 1.21 | |||||
| FCF per share | CNY | -0.96 | -0.96 | |||||
| Free cash flow | CNY m | -435 | -206 | |||||
| Net debt | CNY m | 1,507 | 1,845 | |||||
| Book value equity | CNY m | 2,906 | 2,809 | |||||
| Book value per share | CNY | 6.31 | 6.03 | |||||
| Number of shares | m | 460.38 | 466.01 | |||||
| DPS (TTM paid) | CNY | 0.08 | 0.00 |
Financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 119.05 | - | |||||
| P/B LTM | x | 3.52 | 0.18 | |||||
| P/S LTM | x | 7.85 | 0.87 | |||||
| P/FCF LTM | x | -23.52 | -2.42 | |||||
| EV/EBITDA LTM | x | 39.45 | 6.93 | |||||
| EV/Sales LTM | x | 9.01 | 4.06 | |||||
| Earnings Yield LTM | % | 0.84% | 21.35% | |||||
| FCF Yield | % | -4.25% | -41.32% | |||||
| Quality | ||||||||
| ROE | % | 2.96% | 3.01% | |||||
| ROIC | % | 0.95% | 0.95% | |||||
| Operating margin | % | 3.67% | 3.67% | |||||
| Gross margin | % | 73.05% | 73.05% | |||||
| FCF/Sales | % | -33.38% | -33.38% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -69.84% | - | |||||
| Sales Growth YoY | % | -19.43% | -33.74% | |||||
| Net Income Growth YoY | % | -70.87% | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | -83.43% | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.93% | 0.00% | |||||
| Dividend Growth | % | -58.96% | - | |||||
| Payout Ratio | % | 110.47% | -16.70% | |||||
| FCF/Debt | x | -0.23 | -0.09 | |||||
| Net Debt/EBITDA | x | 5.07 | 5.07 | |||||
| EBIT/Net interest | x | 0.88 | 0.88 | |||||
| Net debt/market cap | % | 14.72% | 369.24% | |||||
| Net debt/Equity | x | 0.52 | 0.66 | |||||
| Gross debt/equity | x | 0.66 | 0.78 | |||||
Company overview
Hainan Poly Pharm. Co., Ltd. operates as a pharmaceutical enterprise in China, engaging in the full spectrum of activities from research and development to the production and distribution of medicinal products. The company supplies Active Pharmaceutical Ingredients (APIs) and also manufactures a diverse array of finished drug formulations. These therapeutic preparations cater to various medical needs, including anti-allergy, non-steroidal anti-inflammatory, antibiotic, and digestive conditions. Key products within their portfolio include desloratadine preparations for anti-allergy treatment, diclofenac formulations for anti-inflammatory relief, azithromycin for injection and clarithromycin preparations as antibiotics, and trimebutine maleate for digestive health. Established in 1992, the company is headquartered in Haikou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hainan Poly Pharm. Co., Ltd (300630.SZ)
Hainan Poly Pharm. Co., Ltd. operates as a pharmaceutical enterprise in China, engaging in the full spectrum of activities from research and development to the production and distribution of medicinal products. The company supplies Active Pharmaceutical Ingredients (APIs) and also manufactures a diverse array of finished drug formulations. These therapeutic preparations cater to various medical needs, including anti-allergy, non-steroidal anti-inflammatory, antibiotic, and digestive conditions. Key products within their portfolio include desloratadine preparations for anti-allergy treatment, diclofenac formulations for anti-inflammatory relief, azithromycin for injection and clarithromycin preparations as antibiotics, and trimebutine maleate for digestive health. Established in 1992, the company is headquartered in Haikou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free